Figure 2. Motor recovery after CCI and treatment with complement inhibitors. a–c, Performance on corner task was assessed weekly after CCI showing that CR2fH and CR2Crry, but not CR2CD59, resulted in significantly faster recovery of forearm laterality compared with vehicle. One-way ANOVA with Bonferroni's multiple comparisons. *p < 0.05, **p < 0.01, ***p < 0.001. d, Motor scores on ladder task were assessed weekly after CCI showing that CR2fH and CR2Crry, but not CR2CD59, resulted in significantly high motor scores throughout 28 d of recovery compared with both vehicle controls and animals treated with CR2CD59. RM two-way ANOVA with Bonferroni's test for multiple comparisons. *p < 0.05, **p < 0.01, ***p < 0.001. Error bars = mean ± SEM. e, Motor scores on day 28 after CCI showing significantly higher scores in CR2Crry and CR2fH-treated mice, but not CR2CD59-treated mice compared with vehicle controls. One-way ANOVA with Bonferroni's multiple comparisons. *p < 0.05, **p < 0.01, ***p < 0.001. f, g, Forelimb and hindlimb errors showing a significant reduction in the number of errors after CR2Crry or CR2fH therapy compared with both CR2CD59 and vehicle. RM two-way ANOVA with Bonferroni's test for multiple comparisons. *p < 0.05, **p < 0.01, ***p < 0.001. Error bars = mean ± SEM.